Advaxis (ADXS) : Monashee Investment Management added new position in Advaxis during the most recent quarter end. The investment management firm now holds 170,611 shares of Advaxis which is valued at $2,335,665 , the company said in a statement filed on Aug 2, 2016 with the SEC.Advaxis makes up approximately 3.57% of Monashee Investment Management’s portfolio.
Other Hedge Funds, Including , Spot Trading L.l.c added ADXS to its portfolio by purchasing 9,239 company shares during the most recent quarter which is valued at $126,482. Advaxis makes up approx 0.02% of Spot Trading L.l.c’s portfolio.Magee Thomson Investment Partners reduced its stake in ADXS by selling 136 shares or 70.83% in the most recent quarter. The Hedge Fund company now holds 56 shares of ADXS which is valued at $439. Capital Analysts sold out all of its stake in ADXS during the most recent quarter. The investment firm sold 1,500 shares of ADXS which is valued $11,700. Bnp Paribas Arbitrage Sa added ADXS to its portfolio by purchasing 1,300 company shares during the most recent quarter which is valued at $11,193.
Advaxis opened for trading at $14.67 and hit $16.05 on the upside on Monday, eventually ending the session at $15.15, with a gain of 6.24% or 0.89 points. The heightened volatility saw the trading volume jump to 32,22,631 shares. Company has a market cap of $520 M.
Many Wall Street Analysts have commented on Advaxis. Company shares were Reiterated by Barclays on Aug 3, 2016 to “Overweight”, Firm has raised the Price Target to $ 20 from a previous price target of $15 .
Advaxis Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy axalimogene filolisbac (ADXS-HPV) targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer Phase I/II in head and neck cancer and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.